EUVIMEDEUVIMED entdecken
Crossref

TFAP2C Attenuates Hypertensive Endothelial Dysfunction by Transcriptionally Activating SPRY4 : A Novel Axis Regulated by miR ‐3656

Yaxuan Ren, Xinxin Fan, Yu Tian, Junbo Zhan, Xinmeng Hu, Yawen Liu, Yi Cheng iD

The FASEB Journal · 30.11.2026 · 40 (22)

DOI: 10.1096/fj.202603091rr ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, online erschienen am 13.11.2026. Verfasst von Yaxuan Ren und 6 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Molecular Epidemiology of Hunan Province, School of Public Health, Hunan Normal University, Changsha, China. Hauptthemen laut MEDLINE: MicroRNAs, Transcription Factor AP-2, Hypertension, Nerve Tissue Proteins. Die Arbeit nennt 23 Literaturangaben. Gefördert von: the National Natural Science Foundation of China, the Natural Science Foundation of Hunan Province, Hengyang Central Hospital-Hunan Normal University Health Science Center Joint Research Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To investigate the role of transcription factor AP‐2γ (TFAP2C) in hypertensive endothelial dysfunction and elucidate the regulatory mechanism of the miR‐3656/TFAP2C/SPRY4 signaling axis. Plasma TFAP2C levels were measured by ELISA in 91 hypertensive patients and 101 healthy controls. Human umbilical vein endothelial cells (HUVECs) and human aortic endothelial cells (HAECs) were subjected to TFAP2C overexpression or knockdown, followed by assessment of cell proliferation, migration, apoptosis, and tube formation. Bioinformatics prediction, ChIP‐qPCR, dual‐luciferase reporter assay, RT‐qPCR, and western blot were used to identify Sprouty4 (SPRY4) as a direct transcriptional target of TFAP2C. Rescue experiments confirmed the mediating role of SPRY4 and the hierarchical relationship of the miR‐3656/TFAP2C/SPRY4 axis. TFAP2C levels were significantly lower in hypertensive patients than in healthy controls (7.40 ± 6.28 vs. 10.04 ± 5.90, p = 0.003) and correlated negatively with blood pressure. TFAP2C overexpression significantly enhanced endothelial proliferation, migration, and tube formation while inhibiting apoptosis, whereas TFAP2C knockdown produced the opposite effects ( p < 0.05). SPRY4 was identified as a direct transcriptional target of TFAP2C. Rescue experiments demonstrated that SPRY4 overexpression partially reversed TFAP2C knockdown‐induced endothelial dysfunction. Furthermore, miR‐3656 negatively regulated the TFAP2C/SPRY4 axis, and SPRY4 overexpression alleviated miR‐3656‐induced impairment of endothelial function. TFAP2C is downregulated in hypertensive patients and exerts protective effects against endothelial dysfunction by transcriptionally activating SPRY4. The miR‐3656/TFAP2C/SPRY4 axis represents a novel regulatory cascade in endothelial dysfunction. TFAP2C may serve as a potential circulating marker associated with endothelial dysfunction in hypertension.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsTranscription Factor AP-2HypertensionNerve Tissue ProteinsIntracellular Signaling Peptides and ProteinsEndothelium, VascularHumansFemaleMaleHuman Umbilical Vein Endothelial CellsCell ProliferationApoptosisCell MovementMiddle AgedEndothelial CellsSignal TransductionCells, Cultured

Stichwörter der Autor:innen

SPRY4TFAP2Cendothelial dysfunctionhypertensionmiR‐3656

Substanzen

MicroRNAsTranscription Factor AP-2SPRY4 protein, humanNerve Tissue ProteinsIntracellular Signaling Peptides and Proteins

Autor:innen und Institutionen

  • Key Laboratory of Molecular Epidemiology of Hunan Province, School of Public Health, Hunan Normal University, Changsha, China.
  • Department of Epidemiology and Biostatistics, School of Public Health of Jilin University, Changchun, China.
  • Institute of Translational Medicine, The First Hospital of Jilin University, Changchun, China.

ORCID-Profile: Yi Cheng

Förderung

  • the National Natural Science Foundation of China
  • the Natural Science Foundation of Hunan Province
  • Hengyang Central Hospital-Hunan Normal University Health Science Center Joint Research Grant

Zitieren

APA

Ren, Y., Fan, X., Tian, Y., Zhan, J., Hu, X., Liu, Y., & Cheng, Y. (2026). TFAP2C Attenuates Hypertensive Endothelial Dysfunction by Transcriptionally Activating SPRY4 : A Novel Axis Regulated by miR ‐3656. The FASEB Journal, 40(22). https://doi.org/10.1096/fj.202603091rr

Vancouver

Ren Y, Fan X, Tian Y, Zhan J, Hu X, Liu Y, et al. TFAP2C Attenuates Hypertensive Endothelial Dysfunction by Transcriptionally Activating SPRY4 : A Novel Axis Regulated by miR ‐3656. The FASEB Journal. 2026;40(22). doi:10.1096/fj.202603091rr

BibTeX
@article{Ren2026,
  author = {Ren, Yaxuan and Fan, Xinxin and Tian, Yu and Zhan, Junbo and Hu, Xinmeng and Liu, Yawen and Cheng, Yi},
  title = {TFAP2C Attenuates Hypertensive Endothelial Dysfunction by Transcriptionally Activating SPRY4 : A Novel Axis Regulated by miR ‐3656},
  journal = {The FASEB Journal},
  year = {2026},
  volume = {40},
  number = {22},
  doi = {10.1096/fj.202603091rr}
}
Kostenlos starten →